Treatment of hypercholesterolemia in patients with diabetes at a family practice office.
Patients with diabetes have an increased risk of developing coronary heart disease (CHD) and therefore need optimal management of hypercholesterolemia. Previous studies have shown that management of these patients remains suboptimal. Our study aimed to determine the extent to which patients with diabetes in a family practice setting in Delaware are being managed according to national guidelines for the management of hypercholesterolemia. Using a retrospective medical chart review, we identified all active patients with diabetes in a family practice office. We determined the percentage of patients who had a low-density lipoprotein (LDL) documented in their chart and the percentage of patients who received LDL screening within the past year. We then stratified the sample into three different categories of LDL level (< 100 mg/dl, 100-129 mg/dl, and > or = 130 mg/dl) and determined the percentage of patients who were on lipid-lowering therapy within each stratum. According to the medical record review, 80.30% of the active patients with diabetes had an LDL recorded in their chart. Of the patients with diabetes, 57.99% had an LDL measurement taken within the past year. Of this group, 41.03% had an LDL < 100 mg/dl, 31.41% had an LDL between 100 and 129 mg/dl, and 25.00% had an LDL > or = 130 mg/dl. Of the total number of patients with an LDL < 100 mg/dl, 53.93% were on lipid-lowering agents, while 38.18% of the patients with an LDL > or = 130 mg/dl were on lipid-lowering agents. Of the patients with an LDL measurement taken in the past year, 67.19% of those with an LDL < 100 mg/dl were on lipid-lowering medications, while 43.59% of patients with an LDL > or = 130 mg/dl were on lipid-lowering medications. In a Delaware family practice office, the screening rate for hyperlipidemia in patients with diabetes is similar to that found in other studies, but still leaves room for improvement. Lipid control rates are somewhat better than the rates reported in previous studies, but they are still not optimal. While many of the patients requiring lipid-lowering therapy are on these medications, a substantial minority has an LDL of < 100 mg/dl without being on medications. Although these findings may reflect patient preference to defer medications, it suggests that there is room for improvement with medical therapy.